Mizuho comes to Avanir's defense after sell-off

|About: Avanir Pharmaceuticals, Inc (AVNR)|By:, SA News Editor

Mizuho rides to the rescue after a report from SA contributor Gravity Research tanked Avanir Pharmaceuticals (AVNR) Wednesday.

Analyst Mario Corso thinks Gravity is "off the mark."

Mizuho apparently has a different take on Nuedexta off-label marketing and AVNR's chances in a patent lawsuit.

AVNR +2.5% premarket